What is hemolysis and what its relationship to PNH?
What happens in PNH is that an acquired mutation in a gene (PIG-A gene) in hematopoietic stem cells results in their inability to form a specific structure (GPI anchor) that carries a variety of cell surface proteins and, included in them, a variety of complement shielding proteins. Because of the loss of the GPI anchor, blood elements lose their cell surface proteins and that makes them more likely to be recognized by the complement system as if they were a foreign body that merit destruction.
Is hemolysis associated with any other conditions besides PNH?
Are there degrees of hemolysis or hemolytic activity?
What are the symptoms of hemolysis? How does it make PNH patients feel?
How is hemolysis treated?
It should be stated that treatment for patients with PNH should be individualized. Patients need to discuss the specifics of their disease and therapeutic options with their providers.
Dr. Shammo is an associate professor of medicine and pathology, Section of Hematology and Stem Cell Transplantation, Division of Hematology/Oncology, at Rush University Medical Center in Chicago where she spearheads the MDS/MPN/Bone marrow failure program. She is also director of the Hematology/Oncology Fellowship Program and CME Course Director in the Division of Hematology/Oncology. After earning a medical degree with honors from Aleppo Medical School in Syria, Dr. Shammo completed internships and residencies in the departments of pathology and internal medicine at McGaw Medical Center of Northwestern University, in Evanston, and a 3-year fellowship in the Division of Hematology/Oncology at University of Chicago. She is board certified in anatomic and clinical pathology, internal medicine, and hematology, and board eligible in oncology. She is also a fellow of the American Society of Clinical Pathologists and American College of Physicians, and is a member of the American Society of Hematology, the American Society of Clinical Oncologists, and the American College of Physicians. Dr. Shammo received the Department of Medicine Service and Teaching Award from Rush University Medical Center in 2003. She has authored or co-authored over 40 publications, including abstracts, posters, book chapters, and online CME activities, as well as articles published in Blood, JCO, Clinical Lymphoma, Journal of Heart and Lung Transplantation, Cytotherapy, and American Journal of Clinical Pathology, among others. Additionally, she functions as a reviewer for several medical journals and as an editor for the Journal of Clinical Oncology. She has designed and was involved as principal investigator for many clinical trials related to chronic myelogenous leukemia, MPN’s, PNH, and myelodysplastic syndromes. As an invited speaker, Dr. Shammo has presented her research at national and international meetings and conferences.